```html

Kawasaki Disease with Lymphadenopathy – A Comprehensive Guide

Overview

Kawasaki disease (KD) is an acute, self‑limited vasculitis that primarily affects medium‑size arteries, especially the coronary arteries. When the disease presents with swollen lymph nodes—typically a unilateral cervical node larger than 1.5 cm—it is referred to as “Kawasaki disease with lymphadenopathy.” The condition is the leading cause of acquired heart disease in children in developed nations.

• Age group: Most cases occur in children under 5 years of age; the median age is 2–3 years.
• Gender: Boys are about 1.5–1.6 times more likely to develop KD.
• Geography & ethnicity: Incidence is highest in East Asia (Japan 239/100,000 children <5 y; Korea 134/100,000). In the United States, the overall incidence is ≈19 per 100,000 children <5 y, with higher rates among Asian‑American and Pacific‑Islander children.
• Prevalence of lymphadenopathy: Swollen lymph nodes are one of the five principal criteria for KD and appear in ≈70–80 % of patients. Isolated cervical lymphadenopathy can be the sole initial sign in “incomplete” KD, making recognition vital.

Although the exact cause remains unknown, early recognition and prompt treatment (intravenous immunoglobulin + aspirin) dramatically reduce the risk of coronary artery aneurysms—from ≈25 % to <5 % when therapy is given within the first 10 days of fever 【1】.

Symptoms

Classic KD is defined by fever lasting ≥5 days plus four of the five principal clinical features. Lymphadenopathy may be the most prominent or the only early sign.

Principal Clinical Features

• Fever: High, often >39 °C (102 °F), remitting‑relapsing, unresponsive to typical antipyretics.
• Conjunctival injection: Bilateral, non‑purulent redness of the bulbar conjunctiva without exudate.
• Oral changes: “Strawberry tongue,” diffuse erythema of the lips and oral mucosa, cracking of the lips.
• Peripheral extremity changes:
  • Acute phase – erythema and edema of the hands/feet.
  • Subacute phase – desquamation (peeling), especially around the nails.
• Polymorphous rash: Usually non‑vesicular, may appear on trunk, extremities, or perineum.
• Lymphadenopathy: Usually a solitary, >1.5 cm, firm, tender cervical node, most often anterior to the sternocleidomastoid muscle.

Associated Symptoms and Findings

• Arthralgia or transient arthritis (more common in older children).
• Irritability, especially in infants.
• Redness of the BCG scar (noted in countries where BCG vaccination is routine).
• Gastrointestinal symptoms – abdominal pain, vomiting, or diarrhea (≈30 % of cases).
• Respiratory signs – cough or mild coryza, often mistaken for a viral infection.

Causes and Risk Factors

The precise trigger for KD remains elusive, but several hypotheses dominate the research landscape.

Potential Etiologies

1. Infectious agents: Seasonal peaks, clustering of cases, and immune‑profile data suggest a post‑infectious trigger. Candidate agents include:
   • RNA viruses (e.g., human coronavirus NL63, adenovirus, RSV).
   • Super‑antigen‑producing bacteria (Staphylococcus aureus, Streptococcus pyogenes).
2. Genetic susceptibility: Genome‑wide association studies have identified polymorphisms in I​T​G​A​M, FCGR2A, and CASP3 that increase risk, especially among East Asian populations.
3. Immune dysregulation: An exaggerated innate immune response with high levels of cytokines (IL‑1β, IL‑6, TNF‑α) leads to endothelial activation and vasculitis.

Risk Factors

• Age <5 y, especially <2 y.
• Male sex.
• Asian ethnicity (Japanese, Korean, Chinese, Pacific Islander).
• Sibling with KD (increased relative risk ≈10‑fold).
• Seasonal clustering (winter‑spring in temperate zones; summer‑autumn in tropical regions).

Diagnosis

KD is a clinical diagnosis; there is no single definitive laboratory test. The presence of fever ≥5 days plus ≥4 principal criteria confirms “complete” KD. “Incomplete” KD is diagnosed when fever plus 2–3 criteria are present together with supporting laboratory or echocardiographic findings.

Clinical Evaluation

• Detailed history focusing on fever pattern, rash, conjunctivitis, oral changes, extremity edema, and lymph node characteristics.
• Physical exam assessing the five principal features and looking for signs of coronary involvement (murmur, gallop).

Laboratory Tests (supportive)

Test	Typical Findings in KD
Complete blood count	Leukocytosis (predominantly neutrophils), normocytic anemia.
Inflammatory markers	Elevated CRP (>3 mg/dL) and ESR (>40 mm/hr).
Platelet count	Thrombocytosis (often >450 ×10⁹/L) after day 7.
Liver enzymes	Mild transaminitis (ALT/AST ↑).
Urinalysis	Sterile pyuria or mild proteinuria.

Imaging

• Echocardiogram: First‑line cardiac imaging. Looks for coronary artery dilation, aneurysms, or decreased function. Recommended at diagnosis, 2 weeks, and 6–8 weeks later.
• Neck ultrasound: Can confirm size & characteristics of the cervical node, helping to rule out bacterial abscess.
• Chest X‑ray or CT (rare): Used if respiratory symptoms or pulmonary involvement suspected.

Diagnostic Criteria Summary

1. Fever ≥5 days.
2. ≥4 of the 5 principal clinical features (including lymphadenopathy).
3. In incomplete KD, supportive labs + echocardiographic abnormalities compensate for missing criteria.

Treatment Options

Goal: halt the inflammatory cascade, prevent coronary artery damage, and relieve symptoms.

First‑Line Therapy

• Intravenous Immunoglobulin (IVIG): 2 g/kg as a single infusion over 10–12 h, administered within the first 10 days of fever. Reduces coronary aneurysm risk >80 %.
• Aspirin: High‑dose (80–100 mg/kg/day) until fever resolves, then transition to low‑dose antiplatelet (3–5 mg/kg/day) for 6–8 weeks or longer if coronary changes persist.

Adjunctive / Refractory Therapy

≈10–20 % of patients are IVIG‑resistant (persistent fever ≥36 h after initial infusion). Options include:

• Second dose of IVIG.
• Corticosteroids: Methylprednisolone 2 mg/kg/day or pulse dosing (30 mg/kg) in severe cases.
• Biologic agents:
  • Infliximab (anti‑TNFα) 5 mg/kg.
  • Anakinra (IL‑1 receptor antagonist) 2–10 mg/kg/day.
• Cyclosporine: Considered for patients with known ITGAM polymorphism or multiple treatment failures.

Supportive Care

• Fluid management – monitor for dehydration due to fever and reduced oral intake.
• Pain control – acetaminophen or ibuprofen for joint pain, avoiding NSAIDs that may increase bleeding risk if high‑dose aspirin is used.
• Antibiotics – only if bacterial superinfection of the lymph node is suspected.

Lifestyle & Follow‑up

• Daily low‑dose aspirin (as prescribed) – importance of adherence.
• Regular cardiology follow‑up with echocardiograms at 2 weeks, 6 weeks, 6 months, and annually if abnormalities persist.

Living with Kawasaki Disease with Lymphadenopathy

While the acute phase resolves in most children within 2–3 weeks, families often wonder how to manage day‑to‑day life.

Practical Tips

• Fever monitoring: Keep a log of temperature readings. Break fever >48 h after IVIG may signal treatment failure.
• Medication schedule: Use a pill organizer for aspirin; set alarms to avoid missed doses.
• Hydration & nutrition: Offer frequent small sips of water, electrolyte solutions, or smoothies. Soft‐solid foods are easier when oral mucosa is painful.
• Activity: Light play is acceptable after fever resolves. Avoid strenuous activity or contact sports for at least 4–6 weeks if coronary involvement is present.
• School re‑entry: Provide a written plan to the school nurse outlining medication timing, signs that require a call to parents, and any activity restrictions.
• Emotional support: Children may feel isolated; consider age‑appropriate books about KD and connect with support groups (e.g., KD Patient Network).

Follow‑up Checklist

1. First cardiology visit within 7–10 days of diagnosis.
2. Repeat echocardiogram at 2 weeks and 6 weeks.
3. Blood work (CBC, CRP, ESR) at each follow‑up to ensure inflammation is waning.
4. Document any new or persistent symptoms (chest pain, shortness of breath, palpitations).

Prevention

Because the exact trigger is unknown, primary prevention is limited. However, some measures can reduce the risk of severe outcomes:

• Prompt evaluation of prolonged fever (>5 days) in children, especially those <5 y.
• Early recognition of the diagnostic criteria—educate parents, daycare staff, and primary‑care providers.
• Vaccination: Maintain up‑to‑date immunizations (e.g., influenza, COVID‑19) to lower the chance of concurrent viral infections that might act as triggers.
• Hand hygiene and avoidance of close contact with children who have evident bacterial/viral pharyngitis, which can mimic KD lymphadenopathy.

Complications

If untreated or inadequately treated, KD can lead to serious sequelae, most of which involve the cardiovascular system.

• Coronary artery aneurysms (CAA): Occur in 15–25 % of untreated children; giant aneurysms (>8 mm) carry a lifelong risk of thrombosis and myocardial infarction.
• Myocarditis & pericarditis: May cause heart failure or arrhythmias.
• Valvular dysfunction: Regurgitation of the mitral or aortic valve has been reported.
• Peripheral arterial stenosis: Rare, but can affect limb perfusion.
• Neurological involvement: Irritability, aseptic meningitis, or stroke (very uncommon).
• Long‑term sequelae: Adults with a history of KD may have premature coronary artery disease despite normal childhood imaging.

When to Seek Emergency Care

References

1. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long‑Term Management of Kawasaki Disease. Circulation. 2017;135:e927‑e999. doi:10.1161/CIR.0000000000000484.
2. World Health Organization. Kawasaki Disease Fact Sheet. Updated 2023. https://www.who.int/…
3. Mayo Clinic. Kawasaki disease. Accessed May 2024. https://www.mayoclinic.org/…
4. CDC. Kawasaki Disease – Clinical Guidance. 2022. https://www.cdc.gov/kawasaki/
5. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis and treatment of Kawasaki disease: A scientific statement from the American Heart Association. Circulation. 2024;149:e466‑e493.
6. Jiang L, Yang J, Li Y, et al. Genetic polymorphisms associated with Kawasaki disease susceptibility: A meta‑analysis. Pediatr Cardiol. 2022;43:1234‑1245.

```